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ABSTRACT 
Heat shock protein 90 (Hsp90) is an ATP-dependent molecular chaperone that plays a role in stabilizing and ac-
tivating more than 200 client proteins. It is required for the stability and function of numerous oncogenic signal-
ing proteins that determine the hallmarks of cancer. Since the initial discovery of the first Hsp90 inhibitor in the 
1970s, multiple phase II and III clinical trials of several Hsp90 inhibitors have been undertaken. This review 
provides an overview of the current status on clinical trials of Hsp90 inhibitors and future perspectives on novel 
anticancer strategies using Hsp90 inhibitors. 
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INTRODUCTION 
Heat shock protein 90 (Hsp90) is one of 
the most abundant proteins in eukaryotes, 
comprising as much as 1 to 2 % of the total 
cellular protein content under non-stressed 
conditions, and increasing approximately 
twofold during environmental stress 
(Buchner, 1999; Welch and Feramisco, 
1982; Whitesell and Lindquist, 2005). In 
human cells, Hsp90 can be found in the cy-
tosol, nucleoplasm, endoplasmic reticulum 
and mitochondria (Chen et al., 2005). Be-
yond Hsp90’s essential role in maintaining 
normal tissue homeostasis, it is an ATP-
dependent molecular chaperone that plays a 
role in stabilizing and activating more than 
200 client proteins, many of which are essen-
tial for constitutive cell signaling and adap-
tive responses to stress (Neckers, 2007; 
Trepel et al., 2010, Whitesell and Lindquist; 
2005). The client proteins include oncogenic 
tyrosine kinase v-Src, mutated oncogene 
Bcr/Abl, receptor tyrosine kinase of the erbB 
family and c-MET, and serine/threonine ki-
nase Raf-1 as well as transcription factors 
such as hypoxia-inducible factor-1α, tumor 
suppressor p53 protein, and steroid receptors 
(Koga et al., 2009; Tsutsumi et al., 2009). 
 
CANCER AND HSP90 
Cancer is a disease of genetic instability 
(Neckers, 2007). For example, in colorectal 
cancers, 5 to 10 genetic alterations appear 
necessary for the generation of the malignant 
phenotype, with the classical example of a 
multistep progression pathway for sporadic 
carcinoma; however, over 10,000 genomic 
events per carcinoma have been found at the 
time of diagnosis (Stoler et al., 1999). The 
genetic instability allows a cancer cell to ac-
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quire the eight hallmarks proposed by Hana-
han and Weinberg (2000, 2011). These are 
(i) self-sufficiency in growth signals; (ii) in-
sensitivity to anti-growth signals; (iii) evad-
ing apoptosis; (iv) sustained angiogenesis; 
(v) tissue invasion and metastasis; (vi) limit-
less replicative potential; (vii) reprogram-
ming of energy metabolism; and (viii) evad-
ing immune destruction. These hallmarks re-
flect genetic alterations in multiple safeguard 
genes responsible for the regulation and tight 
coordination of diverse processes, such as 
cell survival, proliferation, growth, differen-
tiation, and motility (Sidera and Patsavoudi, 
2014). This genetic plasticity allows cancer 
cells to escape the precise molecular target-
ing of a single signaling node or pathway, 
making them ultimately non-responsive to 
molecularly targeted therapeutics (Neckers, 
2007). Each cancer chemotherapeutic has 
targeted proteins associated with multiple 
hallmarks, though none have been able to 
simultaneously affect all of them (Sidera and 
Patsavoudi, 2014). 
Hsp90 consists of a central node in sig-
naling networks and plays a pivotal role in 
the acquisition and maintenance of each of 
these capabilities (Neckers, 2007). There-
fore, inhibition of Hsp90 leads to the degra-
dation of these oncogenic clients and abro-
gates the six hallmarks of a cancer cell sim-
ultaneously. Therefore, targeting Hsp90 ap-
pears to be a reasonable anticancer strategy.  
 
HSP90 INHIBITORS 
Hsp90 inhibitors bind to Hsp90 and in-
hibit Hsp90 function by competing with ATP 
binding, thereby freezing the chaperone cy-
cle, which in turn decreases the affinity of 
Hsp90 for client proteins and leads to pro-
teasome-mediated client protein degradation 
(Tsutsumi et al., 2009). Although Hsp90 is 
highly expressed in most cells, Hsp90 inhibi-
tors kill cancer cells selectively compared to 
normal cells (Kamal et al., 2003). This ther-
apeutic selectivity results from the activated, 
high-affinity chaperone of Hsp90 in tumors 
(Kamal et al., 2003). Based on the above, 
Hsp90 has emerged as an exciting and prom-
ising new target for the development of new 
antineoplastic agents for a variety of human 
cancers in the last two decades. 
In 1970, the benzoquinone ansamycin 
antibiotics were first isolated (DeBoer et al., 
1970). These include geldanamycin (GA), 
which was found in a search for compounds 
able to revert the transformed phenotype of 
v-src transformed 3T3 cells (Whitesell et al., 
1992). However, an in vitro kinase assay re-
vealed that GA neither directly interacts with 
Src nor inhibits its phosphorylating activity. 
Consequently, Hsp90 was identified as the 
direct target of GA (Whitesell et al., 1994). 
GA was shown to mimic the structure adopt-
ed by ATP in the N-terminal nucleotide-
binding pocket of Hsp90, thus leading to se-
lective inhibition of ATP binding and hy-
drolysis and, in turn, to the depletion of on-
cogenic Hsp90 clients (Supko et al., 1995). 
GA alters chaperone function and drives the 
degradation of many Hsp90 client proteins 
by stimulating Hsp90-mediated presentation 
to the ubiquitin–proteasome machinery. 
Consequently, the client proteins cannot at-
tain their active conformation and are de-
graded by the proteasome (Mimnaugh et al., 
1996). Although GA is broadly cytotoxic in 
vitro, its poor solubility and intolerable liver 
toxicity in vivo precluded clinical trials 
(Supko et al., 1995). In the last decade, there 
has been a considerable increase in the dis-
covery of Hsp90 inhibitors, progressing from 
first-generation derivatives of natural prod-
ucts to second-generation fully synthetic 
small molecules (Neckers, 2007; Sidera and 
Patsavoudi, 2014). Less toxic agents than 
GA, namely, 17-AAG (17-Allylamino-17-
demethoxy- geldanamycin) and 17-DMAG 
(17-dimethylaminoethylamino-17-demetho-
xy-geldanamycin), have proceeded to clini-
cal trials.  
 
17-AAG (Tanespimycin) 
17-AAG was the first Hsp90 inhibitor to 
enter clinical trials. In vitro and in vivo, it 
has shown antitumor activity in various pre-
clinical models, such as colon, breast, ovari-
an, and melanoma tumors (Neckers, 2007; 
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Saif et al., 2013). As 17-AAG is not water-
soluble and requires a diluent, including egg 
phospholipid and 4 % DMSO, hypersensitiv-
ity reactions were observed in the phase I tri-
al (Whitesell and Lin, 2012). Taken together, 
several phase II studies of single agent 17-
AAG have been performed since 1999 
(Gartner et al., 2012; Neckers, 2007; Saif et 
al., 2013). However, given the lack of re-
sponse and apparent toxicity, including fa-
tigue, nausea, vomiting, diarrhea, and trans-
aminase elevations, phase II studies in pa-
tients with metastatic breast cancer and met-
astatic melanoma were terminated early 
(Gartner et al., 2012; Pacey et al., 2012). 
 
17-DMAG (Alvespimycin) and IPI-504  
(Retaspimycin) 
To overcome the formulation issues with 
17-AAG, 17-DMAG (Alvespimycin) and 
IPI-504 (Retaspimycin) was developed as its 
water-soluble analog. Alvespimycin is asso-
ciated with a longer plasma half-life, greater 
oral bioavailability, and less extensive me-
tabolism (Jhaveri et al., 2012). In preclinical 
studies, it produced superior antitumor activ-
ity and lower toxicity compared with 17-
AAG (Eiseman et al., 2005; Jhaveri et al., 
2012). A phase I trial of 17-DMAG for ad-
vanced solid tumors revealed clinical activity 
in castration-refractory prostate cancer 
(complete response), melanoma (partial re-
sponse), renal cancer, and chondrosarcoma 
(stable disease) (Pacey et al., 2011). In a 
phase I trial of 17-DMAG for acute myeloid 
leukemia (AML), the drug was well tolerated 
and anti-leukemia activity was observed in 3 
of 17 evaluable patients (Lancet et al., 2010). 
A phase II clinical trial of intravenous 17-
DMAG for HER2-positive breast cancer was 
terminated for unknown reasons (Squibb, 
2011). 
IPI-504 has reached phase III clinical tri-
als. In a randomized, phase III trial of IPI-
504 conducted in patients with metastatic 
and/or unresectable gastrointestinal stromal 
tumors (GIST), the trial was terminated early 
due to the occurrence of four on-treatment 
deaths in the IPI-504 arm. These deaths were 
considered drug-related and included renal 
failure, liver failure, metabolic acidosis, and 
cardiopulmonary arrest (Demetri et al., 
2010). In contrast, in some phase II studies, 
including patients with non-small cell lung 
cancer (NSCLC) (Sequist et al., 2010) and 
HER2-positive breast cancer (Modi et al., 
2013), IPI-504 had an acceptable safety pro-
file, with infrequent transaminase elevations.  
 
Second- and third-generation HSP90  
inhibitors 
The impressive growth in interest in 
Hsp90 is evident in both the academic and 
patent literature and resulted in the discovery 
and pre-clinical testing of an array of new 
synthetic inhibitors. Seventeen agents have 
undergone clinical trials and nine remain un-
der clinical investigation (Neckers and 
Trepel, 2014). Although no Hsp90-targeting 
agents have yet achieved an approved indica-
tion in the treatment of any cancer, several 
structurally distinct Hsp90 inhibitors are cur-
rently being evaluated for anticancer activity 
in several phase III clinical trials. These new 
agents share the ability to bind the N-
terminal ATPase site of Hsp90 with higher 
affinity than the natural nucleotides and pre-
vent the chaperone from cycling between its 
ADP- and ATP-bound conformations 
(Whitesell and Lin, 2012). Currently, Hsp90 
inhibitors are being evaluated in 52 clinical 
trials (National Cancer Institute, 2014a). 
AUY922 (Novartis) and STA-9090 (gane-
tespib, Synta) are furthest in development 
(Whitesell and Lin, 2012).  
Currently, AUY922 is being evaluated in 
13 clinical trials (National Cancer Institute, 
2014a), including nine phase II trials in pa-
tients with NSCLC, gastrointestinal stromal 
tumor (GIST), and metastatic pancreatic 
cancer (Table 1). Common adverse effects of 
AUY922 have included diarrhea, nausea, fa-
tigue, vomiting, and ocular toxicities (Sessa 
et al., 2009). In a phase II trial of AUY922 
monotherapy in patients with advanced 
NSCLC, preliminary clinical activity was 
seen with partial responses in 13 % (Garon et 
al., 2012). Numerous phase II monotherapy 
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trials are underway across a variety of ma-
lignancies (Whitesell and Lin, 2012). 
STA-9090 is an investigational small 
molecule inhibitor of Hsp90 that has favora-
ble pharmacologic properties that distinguish 
the compound from other first- and second-
generation Hsp90 inhibitors in terms of po-
tency, safety, and tolerability (He et al., 
2014). This agent displayed a 20-fold supe-
rior potency to 17-AAG in a panel of 57 
transformed cell lines of both hematologic 
and solid tumors (Ying et al., 2012). It has 
reached phase III clinical trials and 12 clini-
cal trials are currently underway (National 
Cancer Institute 2014a) (Table 2). In a multi-
center phase II study of STA-9090 mono-
therapy in patients with advanced NSCLC, 
durable objective responses and disease sta-
bilization occurred in the majority of patients 
with disease harboring ALK gene rear-
rangements that were crizotinib-naïve (So-
cinski et al., 2013). The most common side 
 
Table 1: Phase II and III trials of AUY922 
Study Phase Treatment arm(s) Patient Population Status 
NCT00708292 I/II AUY922 vs. AUY922 + Bortezomib 
Relapsed or Refractory Multiple 
Myeloma Completed 
NCT01854034 II AUY922 Non Small Cell Lung Cancer Recruiting 
NCT01484860 II AUY922 Metastatic Pancreatic Cancer Terminated 
NCT01668173 II AUY922 Myeloproliferative Neoplasms Recruiting 
NCT01646125 II AUY922 vs. Doce-taxel vs. Pemetrexed 
Advanced Non Small Cell Lung 
Cancer Recruiting 
NCT00526045 I/II AUY922 Breast Cancer and Hematologic Neoplasms Completed 
NCT01485536 II AUY922 refractory or recurrent lymphoma Active, not recruiting 
NCT01271920 II AUY922 + Trastuzumab  
Advanced HER2-positive Breast 
Cancer Completed 
NCT01259089 I/II AUY922 + Erlotinib Stage IIIB-IV Non-Small Cell Lung Cancer 
Active, not 
recruiting 
NCT01752400 II AUY922 Advanced ALK-positive NSCLC Recruiting 
NCT01084330 II AUY922 vs. Docet-axel vs. Irinotecan Advanced Gastric Cancer Terminated 
NCT01404650 II AUY922 Refractory Gastrointestinal Stro-mal Tumor Recruiting 
NCT01402401 II AUY922 + Trastuzumab Advanced Gastric Cancer Terminated 
NCT01361945 I/II AUY922 ER+ HER2+ Advanced Breast Cancer Withdrawn 
NCT01389583 II AUY922 Gastrointestinal Stromal Tumor Recruiting 
NCT01922583 II AUY922 Stage IV Non-small Cell Lung Cancer Recruiting 
NCT01124864 II AUY922 Non-small-cell Lung Cancer Active, not recruiting 
NCT01024283 I/II AUY922 Advanced Solid Malignancies Terminated 
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effects were diarrhea, fatigue, nausea, and 
anorexia, which have been manageable with 
standard care. It is notable that, in contrast to 
AUY922, no ocular toxicity has been report-
ed for STA-9090. The clinical activity of 
monotherapy was observed in heavily pre-
treated NSCLC, breast cancer, gastric can-
cer, melanoma, and colon cancer (Whitesell 
and Lin, 2012). 
 
COMBINATION ACTIVITY OF HSP90 
INHIBITORS 
Single agent activity for Hsp90 inhibitors 
has been disappointingly modest against 
heavily pretreated cancers in clinical trials 
that have been reported to date (Trepel et al., 
2010; Whitesell and Lin, 2012). Whitesell et 
al. (2012) suggested this issue might be in-
trinsic to the target itself and that Hsp90 in-
hibition could serve as a platform for the as-
sembly of specific multi-drug chemothera-
peutic regimens that will more effectively 
control disparate cancers. Preclinical data 
from various types of in vitro and in vivo 
cancer models suggest that Hsp90 inhibitors 
have the ability to enhance the activity of 
other anticancer strategies, including chemo-
therapy, kinase inhibitors, and radiation ther-
apy, to achieve synergistic or additive anti-
tumor effects, and to potentially overcome 
drug resistance (Jhaveri et al., 2014). This 
has formed the basis for rational combination 
trials of Hsp90 inhibitors with other cancer 
therapeutic agents. 
 
Chemotherapy 
Combinations with several classes of cy-
totoxic chemotherapeutic agents have now 
reached clinical trial. Docetaxel has been 
combined with STA-9090 and IPI-504 in a 
clinical trial of NSCLC. A phase III trial of 
STA-9090 in combination with docetaxel 
versus docetaxel alone in patients with ad-
vanced NSCLC is ongoing (Goss et al., 
2012). Recently, Synta Pharmaceuticals 
Corp. announced the results from the final 
analysis of this trial. For chemo-sensitive pa-
tients in particular, the improvements in pro-
gression-free survival and overall survival 
with STA-9090 and docetaxel were encour-
aging (Synta Pharmaceuticals Corp., 2014). 
The phase II randomized trial that evaluated 
the efficacy and safety of IPI-504 plus docet-
axel compared to placebo plus docetaxel in 
226 patients with NSCLC was completed. 
Although the safety profile of IPI-504 plus 
docetaxel was comparable to docetaxel and 
placebo, IPI-504 did not meet its pre-
specified efficacy endpoints for demonstrat-
ing an improvement in overall survival 
(Infinity Pharmaceuticals, 2013). 
 
Kinase inhibitors 
Hsp90 inhibition may also represent an 
effective strategy to overcome or delay the 
development of tyrosine kinase inhibitor re-
sistance (Neckers and Trepel, 2014). Preclin-
ical and clinical examples of crizotinib-
resistant ALK mutations responding to 
Hsp90 inhibition have also been reported 
(Socinski et al., 2013). Furthermore, syner-
gistic growth inhibition in MET-driven tu-
mor models upon combining an Hsp90 in-
hibitor and a kinase inhibitor targeting this 
Hsp90-dependent kinase was recently re-
ported (Miyajima et al., 2013). A phase II 
clinical trial evaluated the safety and efficacy 
of crizotinib and STA-9090 in ALK-positive 
lung cancers, and evaluation of the clinical 
benefit of STA-9090 in combination with si-
rolimus for patients with unresectable or 
metastatic malignant peripheral nerve sheath 
tumor is ongoing (National Cancer Institute, 
2014a).  
 
Radiation therapy 
Radiation therapy is a well-established 
standard treatment option for localized and 
locally advanced cancer. An approach to 
augment the efficacy of radiation therapy 
without simultaneously increasing the risk to 
normal tissues is biologic escalation of the 
radiation dose to the tumor through the use 
of tumor-specific radiosensitizing agents 
(Gandhi et al., 2013). Targeting Hsp90 is a 
radiosensitizing approach for cancer cells in 
which Hsp90 is overexpressed compared to 
normal cells. Hsp90 inhibition offers the 
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Table 2: Phase II and III trials of STA-9090 
Study Phase Treatment arm(s) Patient Population Status 
NCT01579994 I/II STA-9090 and  crizotinib ALK Positive Lung Cancers Recruiting 
NCT01368003 II STA-9090 Castration-Resistant Prostate Can-cer vs. STA9090 with Dutasteride Withdrawn 
NCT01111838 II STA-9090 Colon /Rectal Cancer Completed 
NCT01273896 II STA-9090 Metastatic Breast Cancer Completed 
NCT01270880 II STA-9090 Castration-Resistant Prostate Can-cer 
Active, not 
recruiting 
NCT01167114 II STA-9090 Advanced Esophagogastric Cancer Active, not recruiting 
NCT02008877 I/II 
STA-9090 vs. 
STA9090 with Siroli-
mus 
Malignant Peripheral Nerve Sheath 
Tumors (MPNST) Recruiting 
NCT01962948 I/II STA-9090 Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting 
NCT01348126 II/III STA-9090 Advanced Non Small Cell Lung Cancervs. STA9090 with Docetaxel 
Active, not 
recruiting 
NCT01200238 II STA-9090 Ocular Melanoma  Recruiting 
NCT01039519 II STA-9090 Gastrointestinal Stromal Tumor  Completed 
NCT01560416 II Fulvestrant vs. Fulves-trant with STA-9090 
Hormone Receptor-Positive, Meta-
static Breast Cancer Recruiting 
NCT01031225 II STA-9090 Stage IIIB or IV Non-Small Cell Lung Cancer 
Active, not 
recruiting 
NCT01227018 II STA-9090 Metastatic Pancreas Cancer Terminated 
NCT01173523 II STA-9090 Relapsed or Refractory Small Cell Lung Cancer  
Active, not 
recruiting 
NCT01551693 II STA-9090 Unresectable Stage III or Stage IV Melanoma 
Active, not 
recruiting 
NCT01677455 II STA-9090 Metastatic Breast Cancer Active, not recruiting 
NCT01236144 I/II STA-9090 vs. Plerixafor vs. AC220 Acute Myeloid Leukemia Completed 
NCT01562015 II STA-9090 ALK-Positive Non-Small-Cell Lung Cancer 
Active, not 
recruiting 
NCT01798485 III STA-9090 
Advanced Non-Small Cell Lung 
Cancer vs. STA9090 with Docet-
axel 
Recruiting 
NCT02012192 I/II Paclitaxel vs. STA9090 with Paclitaxel 
Metastatic, p53-mutant, Platinum-
resistant Ovarian Cancer 
Not yet  
recruiting 
NCT01590160 I/II STA-9090 Malignant Pleural Mesothelioma Recruiting 
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possibility of radiosensitization through 
broad downregulation of multiple critical ra-
dioresistance pathways whose components 
are members of the Hsp90 clientele, such as 
signal transduction pathways (PI3K-Akt-
mTOR) and DNA damage response path-
ways (ATR/Chk1) (Gandhi et al., 2013). 17-
AAG has been validated as a potential thera-
peutic agent that can be used at clinically 
relevant doses to enhance cancer cell sensi-
tivity to radiation. 17-AAG has been report-
ed to potentiate both the in vitro and vivo ra-
diation response of cervical carcinoma cells 
(Bisht et al., 2003). STA-9090 acts as a radi-
osensitizer to potentiate the effects of low-
dose radiation in vitro (He et al., 2014). At 
the molecular level, it was found that com-
bined Hsp90 inhibition and radiation impact-
ed several overlapping pathways that led to 
cell cycle dysregulation, diminished DNA 
repair capacity, and enhanced apoptosis. 
Currently, a phase I clinical trial of STA-
9090 given together with capecitabine and 
radiation in patients with locally advanced 
rectal cancer is ongoing (National Cancer 
Institute 2014a). 
 
HSP90 INHIBITORS IN BLADDER 
CANCER  
For a decade, we have investigated the 
possibility of the clinical application of 
HSP90 inhibitors, with a particular focus on 
bladder cancers. Similar to other malignan-
cies, the single agent activity of Hsp90 inhib-
itors has been disappointingly modest 
against bladder cancers and there are no ac-
tive clinical trials. 
 
Combination of Hsp90 inhibitor in chemo-
radiotherapy-based bladder-sparing treat-
ment for muscle-invasive bladder cancer 
Bladder cancer is the fifth most common 
cancer in the US, with 74,690 new patients 
and 15,580 deaths being estimated in 2014 
(National Cancer Institute 2014b). Muscle-
invasive bladder cancer (MIBC) accounts for 
one-third of all bladder cancer cases (Lee 
and Droller, 2000). Radical cystectomy with 
urinary diversion, the reference standard 
treatment for MIBC, is associated with high 
complication rates and compromises quality 
of life (QOL) as a result of long-term effects 
on urinary, gastrointestinal and sexual func-
tion, and changes in body image. As a socie-
ty ages, the number of elderly patients unfit 
for radical cystectomy as a result of comor-
bidity will increase, and the demand for 
bladder-sparing approaches for muscle-
invasive bladder cancer will thus inevitably 
increase (Koga and Kihara, 2012). To over-
come these issues, bladder-sparing ap-
proaches combined with various modalities 
have been investigated (Housset et al., 1993; 
Koga et al., 2012; Shipley et al., 2002). 
Above all, bladder-sparing approaches in-
corporating chemoradiotherapy (CRT) im-
proves QOL while not compromising sur-
vival outcomes in MIBC patients. In most 
bladder-sparing protocols, complete response 
to induction CRT is a prerequisite for blad-
der preservation, also indicating favorable 
oncological outcomes (Koga et al., 2012, 
2008; Rodel et al., 2002: Shipley et al., 
1987). 
We reported that erbB2 and NFkB over-
expression play a potential role in CRT re-
sistance and are independently associated 
with unfavorable survival with marginal sig-
nificance in MIBC patients treated with in-
duction CRT plus cystectomy (Inoue et al., 
2014; Koga et al., 2011). This indicates that 
erbB2 and NFkB are putative therapeutic 
targets for treatments aimed at improving 
CRT sensitivity in MIBC. Hsp90 inhibitors 
at low concentrations, which did not exert 
cytocidal effects but inactivated erbB2, Akt, 
and NFkB, and efficiently sensitized bladder 
cancer cells to in vitro and in vivo CRT more 
effectively than sole or combined inhibition 
of erbB2 and Akt (Yoshida et al., 2011). 
Based on these results, we sought to ex-
amine the potential role of Hsp90 inhibitors 
in overcoming the CRT resistance and to en-
courage clinical trials of Hsp90 inhibitors in 
patients with MIBC. We are planning a clin-
ical trial of STA-9090 in combination with 
CRT in patients with MIBC.  
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Combination of Hsp90 inhibitor in  
cisplatin-based chemotherapy, targeting 
bladder cancer-initiating cells 
Although up to 70 % of patients with ad-
vanced bladder cancer show an initially good 
tumor response to cisplatin (CDDP)-based 
combination chemotherapy, more than 90 % 
of patients develop recurrences and eventual-
ly die from the disease (Saxman et al., 1997). 
From the viewpoint of cancer stem cell biol-
ogy, this phenomenon can be explained as 
follows: systemic chemotherapy kills the 
majority of bladder cancer cells, leading to 
the clinical result of tumor shrinkage; how-
ever, a small population of chemo-resistant 
cancer cells that possess tumorigenic capaci-
ty is spared, and they allow tumor regrowth 
(Dean et al., 2005). The existence of a cellu-
lar hierarchy within epithelial tumors has 
been advocated, and at the top of the hierar-
chy is a population of tumor-initiating cells 
(T-ICs) or cancer stem cells. The complete 
eradication of T-ICs is necessary to ‘‘cure’’ 
advanced cancer patients.  
We isolated bladder cancer-initiating 
cells (BCICs) from human bladder cancer 
cell lines based on their CD44 expression 
status (Tatokoro et al., 2012). These BCICs 
were more resistant to CDDP and exhibited 
more activity in the Akt and ERK oncogenic 
signaling pathways when compared with 
their CD44- counterparts. Hsp90 inhibitors 
that simultaneously inactivated both Akt and 
ERK signaling at noncytocidal concentra-
tions synergistically potentiated the cytotoxic 
effects of cisplatin on BCICs in vitro and 
successfully sensitized cisplatin-resistant 
BCIC-derived tumor xenografts to cisplatin. 
These data encourage clinical trials of Hsp90 
inhibitors as they may improve therapeutic 
outcomes of CDDP-based combination 
chemotherapy against advanced bladder can-
cer. 
 
FUTURE PERSPECTIVES 
Hsp90 drug conjugates as novel cancer-
specific anticancer agents 
An Hsp90 inhibitor drug conjugate 
(HDC) platform technology was recently ad-
vocated (Synta Pharmaceuticals, 2014). 
HDCs increase cancer cell killing while re-
ducing collateral damage to normal cells. 
They are small-molecule drugs consisting of 
an Hsp90 inhibitor (targeting moiety) joined 
to an anti-cancer agent (payload) via a cleav-
able chemical linker that is optimized for 
controlled release of the payload drug inside 
cancer cells (Ying et al., 2014). The active 
Hsp90 in tumors acts as a magnet to attract 
the Hsp90-inhibitor moieties in HDCs, 
bringing the entire HDC molecule preferen-
tially to tumors. This results in higher con-
centration and longer duration of the active 
payload drug inside cancer cells than occurs 
with standard administration of unconjugated 
chemotherapy or other payloads. The en-
hanced delivery creates the potential for 
greater cancer cell killing and reduced side 
effects. 
HDCs with over 40 different payloads 
have been developed, including chemothera-
peutics, kinase inhibitors, hormone therapies, 
immunomodulators, and epigenetic modifi-
ers, creating the potential for next-generation 
compounds in each of these categories (Ying 
et al., 2014). Examples of payloads include 
topoisomerase inhibitors (camptothecin), mi-
crotubule modulators (taxanes), proteasome 
inhibitors (carfilzomib), and CDK inhibitors 
(flavopiridol). This innovative approach 
could have great potential for reducing the 
adverse effects of existing chemotherapies as 
well as overcoming drug resistance mecha-
nisms in multiple human malignancies. 
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